Clinical efficacy of Diabecon in treatment of type 2 diabetes mellitus, in newly diagnosed diabetic patients and in those on drug treatment (Glibenclamide and Metformin) in Erbil Governarate-Kurdistan Region/ Iraq.


Abstract:Various herbs have been found beneficial in the management of type 2 diabetes and aregaining considerable recognition in the management of type 2diabetes worldwide. The presentstudy was planned to evaluate the clinical efficacy of Diabecon (Herbal formulation) as a monotherapy and also as an adjunct with other oral hypoglycemic agents, in the management of type 2DM. A total of 80 patients of either sex, between 30-68 years of age, in whom the diagnosis oftype 2 diabetes was confirmed, and who were willing to give informed consent were included inthe study.All enrolled patients were categorized into 4 groups. Group A included 20 newlydiagnosed patients who were not consuming any oral hypoglycemic agent (OHA), while group Bincluded 20 patients who were already consuming glibenclamide but were not controlled, whilegroup C included 20 patients who were already consuming metformin but were not controlledand lastly group D included 20 patients who were already consuming glibenclamide andmetformin combination but were not controlled. Patients from all the groups were advised toconsume Diabecon at a dose of 2 tablets, three times daily (30 minutes) before meal for a periodof 3 months, either as monotherapy for group A or as adjunct in the other three groups.For all the patients, fasting blood glucose (FBG) and postprandial blood glucose (PPG)were assessed at the time of enrollment and thereafter every month, for 3 months, WhileGlycoselated haemoglubin (HbA1c), Total cholesterol (TC), Triglyceride (TG), High densitylipoprotein-Cholesterol (HDL-c), Low density lipoprotein-Cholesterol (LDL-c), Basal seruminsulin, C-peptide and body weight (BW) were assessed at the time of enrollment and after 3months.Diabecon significantly reduced FBG, PPG and HbA1c in all groups, which indicating animproved glucose homeostasis under the influence of this herbal formulation. There was a mildimprovement in serum basal insulin and C-peptide level after using Diabecon either asmonotherapy or as adjunct to glibenclamide, metformin or glibenclamide and metformincombination in those with type 2 diabetic patients who were not controlled by such oralhypoglycemic agent. Diabecon caused improvement of lipid profile including TC, TG and LDL-cto a variable extent in all groups except for group B. Its main effect is on the reduction of TCwhich could be beneficial since hypercholesterolemia is strongly associated with cardiovasculardisease. A significant reduction in body weight was noticed at the end of the study among allgroups except in group B who showed an increase in body weight but it was not significant. Thisweight reduction is a desired effect in type 2 diabetic patients and may play a role in improvinginsulin resistance. Most of the patients reported a sense of well-being and no side effect wererecorded either by patient or observer except rare cases of gastric upset.Therefore, it may be concluded that Diabecon is clinically effective herbal formulation inthe management of type 2 diabetes either as a monotherapy in newly diagnosed patients or as anadjunct therapy in patients on conventional OHAs.